Satoh, Michihiro http://orcid.org/0000-0003-1688-1239
Yoshida, Tomoya
Metoki, Hirohito
Murakami, Takahisa
Tatsumi, Yukako
Hirose, Takuo
Takabatake, Kyosuke
Tsubota-Utsugi, Megumi
Hara, Azusa
Nomura, Kyoko
Asayama, Kei
Kikuya, Masahiro
Hozawa, Atsushi
Imai, Yutaka
Ohkubo, Takayoshi
Funding for this research was provided by:
Scientific Research, Ministry of Education, Culture, Sports, Science and Technology, Japan (21K10478, 21K10452, 18K17396, 20K08612, 19K19466, 21K19670, 21K19670, 19H03908)
Bayer Yakuhin, Ltd (The Academic Contributions)
Health Science Center Research Grant
Pfizer Japan Inc. (The Academic Contributions)
Daiichi Sankyo Co.,Ltd. (Scholarship donations)
Research Support (Astellas Pharma Inc.)
Takeda Pharmaceutical Co.,Ltd. (Research Support)
Takeda Science Foundation
Keio University (internal research grants)
Teikyo University (ACRO Incubation Grants)
the Japan Arteriosclerosis Prevention Fund
Grant–in–aid from the Ministry of Health, Labor, and Welfare, Japan (H29–Junkankitou–Ippan–003)
Article History
Received: 24 December 2022
Accepted: 20 March 2023
First Online: 27 March 2023
Competing interests
: M.S. received the Scholarship (Academic Contribution) from Bayer Yakuhin, Ltd. H.M., K.A., Y.I., and T.O. concurrently held the position of director of the Tohoku Institute for the Management of Blood Pressure, supported by Omron Healthcare Co., Ltd. K.A. received honoraria from Takeda Pharmaceutical Co., Ltd. K.A. and T.O. received a joint research grant from Omron Healthcare Co., Ltd. The Division of Integrative Renal Replacement Therapy was financially supported by Chugai Pharmaceutical Co., Ltd., Terumo Corporation, and JMS Co., Ltd. All other authors state no competing interest.